The treatment of oestrogen-escaped carcinoma of the prostate with estramustine phosphate.
30 patients with oestrogen-escaped carcinoma of the prostate have been treated with estramustine phosphate (Estracyt). 27% showed a partial objective response and 33% had a subjective response. The terms used for defining a response are challenged and it is recommended that comparative controlled trials are necessary to judge the place of this drug in the management of advanced prostatic cancer.
D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D004967:Estrogens; D009588:Nitrogen Mustard Compounds; D004961:Estramustine